|Bid||2.86 x 800|
|Ask||2.87 x 3000|
|Day's Range||2.78 - 2.92|
|52 Week Range||2.35 - 4.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.60|
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
BEDMINSTER, N.J. and DUBLIN, Ireland, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced that the primary results of Amarin’s cardiovascular outcomes study of Vascepa, the REDUCE-IT study, have been accepted for presentation at the 2018 Scientific Sessions of American Heart Association (AHA) on November 10, 2018 in Chicago, Illinois. The presentation, classified as late-breaking clinical trial results, is scheduled to commence at 2:16 pm Central Time and listed as Main Event 1 for that timeframe. A link to this notice is provided at: http://www.abstractsonline.com/pp8/#!/4682/presentation/59402. This acceptance as a presentation of late-breaking clinical trial results is based on the ability of REDUCE-IT to address a critical question in cardiovascular prevention. The AHA has reviewed the design of the REDUCE-IT study, however, they have not yet seen the results of the study. As Amarin has guided in the past, topline results of this study are anticipated to be made public prior to the end of this month, September 2018.
A look at the shareholders of Amarin Corporation plc (NASDAQ:AMRN) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while hugeRead More...
A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker Amarin.
Clinical trial results on the way could change the way investors feel about these biotech stocks before the leaves start falling.
The biotech sector notched strong gains last week, capitalizing on the positive overall market sentiment, set in motion by the trade deal between the U.S. and Mexico. Here are a few catalysts that could ...
REDUCE-IT Study Remains On-Track for Report of Top-Line Results Before the End of September 2018. BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 26, 2018-- Amarin Corporation plc, a biopharmaceutical company ...
NEW YORK, Aug. 21, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of pdvWireless, ...
Amarin and Geron are both racing toward major binary events that could pay off for early shareholders in a big way.
On a per-share basis, the Dublin-based company said it had a loss of 12 cents. Losses, adjusted for stock option expense, were 10 cents per share. The results did not meet Wall Street expectations. The ...
REDUCE-IT™ Study On-Track for Reporting Top-Line Results by the End of September 2018. Management to Host Conference Call at 7:30 a.m. ET Today. BEDMINSTER, N.J., and DUBLIN, Ireland, Aug. 01, 2018-- Amarin ...
BEDMINSTER, N.J. and DUBLIN, Ireland, July 26, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, along with its commercial partner, Biologix FZCo, a pioneer in the distribution of pharmaceutical and biological products in the Middle East and North Africa (MENA) region, today announced that United Arab Emirates (UAE) Ministry of Health and Prevention has approved Vascepa® (icosapent ethyl) capsules as a prescription medication for use as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (TG 500 mg/dL) hypertriglyceridemia in the UAE. This approval is a result of the collaborative effort by the parties since the start of their 2016 agreement to register and commercialize Vascepa in multiple countries in the MENA region.
Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's second quarter 2018 financial results and provide an operational update on August 1 at 7:30 a.m. EDT. Investors and others should note that Amarin communicates with its investors and the public using the company website (http://www.amarincorp.com/), the investor relations website (http://investor.amarincorp.com/), including but not limited to investor presentations and investor FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media, and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin's next major clinical catalyst is close at hand, but investors may want to stick to the sidelines with this high-risk stock.
On Friday, June 29, 2018, US markets saw broad based gains with six out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
On June 28, Amarin (AMRN) stock rose ~10% after the company announced the occurrence of the last patient visit in its REDUCE-IT study, a long-term cardiovascular outcome study, of its fish oil product Vascepa. Amarin’s Vascepa was approved by the FDA (U.S. Food and Drug Administration) in 2012. Despite the large number of Americans having high triglyceride levels and the potentially high patient base for Vascepa, the company is still seeing lower-than-expected sales from the pill.
Amarin Corporation plc (AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that the last patient study visit has occurred in its potential landmark cardiovascular outcomes study, REDUCE-IT™. The company also reiterated that it anticipates having top-line results for this important study reported before the end of Q3 2018. As is typical of large, multi-national, long-term outcomes studies, the final steps preceding REDUCE-IT completion include resolving remaining queries to contribute to a robust and accurate database. This “cleaning” process is characteristically intensive and time consuming.
BEDMINSTER, N.J. and DUBLIN, Ireland, June 25, 2018-- Amarin Corporation plc, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, ...